Quick Answer
Kymera Therapeutics, Inc. reported Net Income of -$311.35 million for fiscal year 2025.
Kymera Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$311.35M | -39.1% |
| 2024 | -$223.86M | -52.3% |
| 2023 | -$146.96M | +5.1% |
| 2022 | -$154.81M | -54.5% |
| 2021 | -$100.22M | -119.8% |
| 2020 | -$45.59M | -10.5% |
| 2019 | -$41.25M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$82.17M | -31.5% | -7.3% |
| June 30, 2025 | -$76.61M | -82.1% | -16.8% |
| March 31, 2025 | -$65.58M | -35.1% | -5.0% |
| September 30, 2024 | -$62.49M | -18.2% | -48.6% |
| June 30, 2024 | -$42.06M | -8.4% | +13.4% |
| March 31, 2024 | -$48.56M | -18.6% | +8.2% |
| September 30, 2023 | -$52.87M | -22.9% | -36.3% |
| June 30, 2023 | -$38.80M | +3.6% | +5.2% |
- Kymera Therapeutics, Inc. showed a decrease of -39.1% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Kymera Therapeutics, Inc.’s net income has declined by 654.9% (from -$41.25 million to -$311.35 million).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: